George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Also, if they're so inclined, DSM can instruct someone to drip feed there shares into to the market as and when they think the price is right, so they're happy too ( and Kev can buy them, which'll make him happy too ! ).
Credit ( pun intended ) where it's due, that's a decent way of solving the cash flow issue and doesn't fundamentally change the value of the company because we've directly swapped equity for stock of the same value.
With Lucas having been a whisker under 10% I wonder if he passed on the opportunity to increase because, under the AIM rules, going over 10% would see him treated as a related party ?
BB
Doesn't seem like this news will drop the SP anyway, so time for a small top-up.
Well done IF. Lets wait for the doom and gloom posts to arrive from the ones hoping to buy on a very low fund raise placing or are just not invested anymore in the company. Roll on the new 2024-2025 Isa allowance
Hmm, wasn't there an outstanding question about the shelf-life of the DSM stock, and does this indicate that it has been confirmed it can be safely extended?
Seems very positive news and hopeful in the near future sales can start to cover costs.
I don’t think it entirely solves the funding issue but this is a huge vote of confidence in PXS. DSM know the company better than anyone and whilst I’m sure PXS leveraged the fact that the stock was of little value to DSM, it’s still a great result for shareholders.
Also very good news that the Irish setup is complete
On the whole, I can't help thinking that this is good news as it saves a messy fund raise that would have almost certainly been done at a lower share price.
It resolves the issue of the fund raiser that has been hanging over our heads for the last 12-15 months and, at the same time, it identifies the further commitment to, and confidence in, the product by DSM
Rns
Very positive runs , Dsm are happy to invest more in the company and it seems sales are booming !
Well I guess DSM are confident in a return.
I think of it as joint IP and share of final product, not just supplying FF. PXS will want to retain control.
I’d take 50% of that huge market, of course we will supply ff to by-health, all other ingredients will be sourced by By health from others .
Remember that whilst BH have the patent, FF as a drug is a joint venture between PXS and BH.
This is different from all the other finds in that it will be classed as a drug in the “territories “ China Taiwan Australia .
Hi gixer,
As usual a great find. Hope all these will materialize soon.
Gixer - Great find!!
The thing that slightly confuses me in all of this is that By-Health seem to have bought in to the efficacies of Fruitflow and seem to be spending a lot of time (and money) into research of its additional properties. They seem extremely confident of the product itself.
Given that, I would have thought that they would at some stage look to be taking a stake in PXS with a view to a by out of the Company. However, there doesn't seem to be a glimmer of that sort of activity at the moment. From what I read of the new Patent, it will be owned by By-Health.
I am not sure that is a problem - the main issue is that this will increase the value of the existing PXS patents and surely will impact on the SP of PXS.
I have said it before but i think a rationale valuation of our current patents is about £40 - £50 M (ie 3 x current SP). This new news gives me confidence that the real value of our patents is somewhere north of that figure. IF we get some form of medicinal approval, the upper limit is. surely a lot more.
Until we get some solid news I fear we will just be stuck around this SP.
An update would be more than welcome.
Sp
Yes it’s all getting very exciting, except the so of course! Maybe a trading update is needed next week ,.
It was "A medicament for preventing and treating cerebral thrombosis" that caught my interest.
Looks like that could happen soon , great find gixer
Fruitflow plus vine tea, that's a new one.
Hope they're successful
"Plant extract composition and application thereof"
2024-03-22 Publication of CN117731721A
Status Pending
"5. The drug for preventing and treating cerebral thrombosis according to claim 4, wherein the dosage form of the drug is a tablet, a capsule or a powder."
"Cerebral thrombosis is one of common ischemic cerebrovascular diseases, and has high death rate and disability rate. The main harm of cerebral thrombosis is to cause vascular occlusion and blood flow interruption, so that cerebral tissues in blood supply areas of blood vessels are ischemic, anoxic, softened and necrotized, and the damage of nerve functions is caused, and the cerebral thrombosis is particularly manifested by hemiplegia, limb numbness, motor confusion, slurred speech, dizziness, blurred vision and the like, and the serious people can suffer from coma, fecal incontinence and even death. In recent years, the dietary structure is changed, the life rhythm is accelerated, cerebral thrombosis is shown to be an increasing incidence, and the ill population tends to be younger, thus bringing great threat to the health of the vast population."
"Compared with the traditional technology, the beneficial effects of the embodiment of the application include:
the plant extract composition comprising the water-soluble tomato concentrate and the ampelopsis grossedentata extract provided by the embodiment of the application has a synergistic effect in improving blood flow, inhibiting platelet aggregation and preventing cerebral thrombosis, and compared with the use of a single extract, the water-soluble tomato concentrate and the ampelopsis grossedentata extract are combined, so that the effect is remarkably improved, the cost is greatly reduced, and the application prospect is very good."
https://patents.google.com/patent/CN117731721A/en?oq=%22CN117731721A%22
From one of the leading news sources for the nutrition industry.
https://www.nutraingredients-asia.com/Article/2024/03/25/byhealth-s-revenue-up-nearly-20-with-protein-probiotics-powder-leading-sales
New video from Dr Wolz
https://www.youtube.com/watch?v=QyQ1HCsC-B0